Showing results (141-150 of 250) with videos related to

Sort By:
Pageof 25
Anticancer Research|November 27, 2008
Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology GroupAngelos K Koutras, George Fountzilas, Urania Dafni, et al.
Breast Cancer Research and Treatment|March 11, 2011
Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) studyGeorge Pentheroudakis, Anna Batistatou, Konstantine T Kalogeras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2009
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanomaDimitrios Pectasides, Urania Dafni, Dimitrios Bafaloukos, et al.
Cancers|November 9, 2024
Molecular Alterations in Paired Epithelial Ovarian Tumors in Patients Treated with Neoadjuvant ChemotherapyAdamantia Nikolaidi, Eirini Papadopoulou, Dimitrios Haidopoulos, et al.
Cancer Causes & Control : CCC|March 1, 2008
Risk associations of melanoma in a Southern European population: results of a case/control studyVasiliki A Nikolaou, Vana Sypsa, Irene Stefanaki, et al.
BMC Clinical Pathology|July 3, 2014
alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studiesTriantafyllia Koletsa, Flora Stavridi, Mattheos Bobos, et al.
Oncology Reports|March 6, 2010
Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative studyKonstantinos Lasithiotakis, George Economou, Helen Gogas, et al.
Clinical Breast Cancer|January 22, 2016
Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer PatientsVasilios Karavasilis, Christos Papadimitriou, Helen Gogas, et al.
Future Oncology (London, England)|September 15, 2025
Real-world safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive/HER2-low metastatic breast cancer: a multicenter retrospective cohort studyElias Kotteas, Εmmanouil Panagiotou, Μaria Grammoustianou, et al.
Plos One|March 19, 2014
Differential expression of the insulin-like growth factor receptor among early breast cancer subtypesGiannis Mountzios, Dimitra Aivazi, Ioannis Kostopoulos, et al.
Pageof 25